Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arteaus sells Emgality royalties to Royalty Pharma in $260mm financing

Executive Summary

Arteaus Therapeutics LLC sold Royalty Pharma all its royalty interests on future global net sales of Emgality (galcanezumab), a calcitonin gene-related peptide (CGRP) antagonist antibody for the prevention of migraine, for $260mm.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies

Advertisement
UsernamePublicRestriction

Register